SPOTLIGHT: Pertuzumab slows breast cancer in study
Roche announced that a combination of Herceptin and pertuzumab slowed the spread of breast cancer. Pertuzumab is the first in a new class of agents known as HER dimerization inhibitors. HDIs block the ability of the HER2 receptor to collaborate with other HER receptor family members. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


